Optimizing LDL-C Lowering and Adherence to Hyperlipidemia Guidelines

Stream link:

8PM ET: https://globalmeet.webcasts.com/starthere.jsp?ei=1707434&tp_key=3a017f1e1c

This activity is part 2 of a 3-part webinar curriculum. Click here to view the other webinars in this curriculum.

Program Description
Hyperlipidemia may occur due to genetic or acquired disorders that increase lipid and low-density Guidelines for hyperlipidemia have established treatment recommendations and thresholds for low-density lipoprotein cholesterol (LDL-C). Despite available treatments, many patients do not achieve guideline-recommended LDL-C levels, resulting in residual cardiovascular risk. Within the care team, pharmacists can educate patients about the importance of adherence to guideline recommendations for LDL-C lowering and help to identify patients who may be candidates for the addition of non-statin therapies. This webinar will examine treatment challenges with statins and factors pointing toward the addition of non-statin therapies in treatment regimens for patients with hyperlipidemia.

Target Audience: Community pharmacists, health system pharmacists, and specialty pharmacists

Type of Activity: Application
Release date: March 27, 2025
Expiration date: May 27, 2025
Learner level: Foundational
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Detect barriers affecting low-density lipoprotein cholesterol control among patients with hyperlipidemia, including statin intolerance and resistance as well as clinical inertia 
• Examine adherence to recommendations outlined in the hypercholesterolemia guidelines for using non-statin therapies in specific patient populations with cardiovascular risk

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-9999-25-010-L01-P. The activity is available for CE credit through May 27, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Joseph Saseen, PharmD, BCPS, BCACP, CLS, has the following relevant financial relationships with commercial interests to disclose:

Other Support (Lipid Monitoring Committee): Amgen (VESALIUS and OCEAN(a))

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta, and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms